Ablitech, Inc., a biotechnology company developing delivery systems for gene silencing and cancer-fighting treatments, today announced that Dr. Daniel Bednarik has been named the Director of the Research Advisory Board.
In his part-time role, Bednarik will assemble and manage a committee of scientists who will provide guidance to the corporation's research efforts, enhance funding, and create partnering opportunities.
Ablitech CEO Ken Malone said, "It is an exciting time for the company as we expand our team and welcome seasoned product development expert Dr. Bednarik. We created this board to gather scientific mass in an advisory context, and Dr. Bednarik’s experience will lead this group to evaluate Ablitech’s data.
"This company is different and what they are trying to do is compelling," commented Bednarik. "It addresses a pivotal technical hurdle that other biotechnology companies are encountering in the delivery of novel drugs, and I want to enable Ablitech’s technology in the way it deserves."
Bednarik continued, "Companies would be ecstatic if there was an efficient, targetedway to deliver nucleic acid-based drugs, and I am ready to hit the ground running."
Currently serving as Director of Genomics and Bioinformatics for Cardiome Pharma Corporation, Bednarik was previously co-founder and Vice President of Cardiovascular Biology for Artesian Therapeutics, Inc. He created the largest known cardiovascular gene expression database for Gene Logic, which served as a novel source of cardiovascular disease data for multiple pharma companies, and grounded the basis for founding Artesian Therapeutics.
Bednarik served as a key scientist for the development of Human Genome Sciences’ (HGS) database and has more than 28 years of experience in the field of virology. His training was completed at Temple University School of Medicine in 1985, and The Johns Hopkins University Oncology Center.
About Ablitech, Inc.: